TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26228543

Group type: COMPARATOR
Intervention: Single vision lenses
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control lens (AirOptix Aqua)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Night and Day lens
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Multifocal lenses
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Proclear Multifocal lenses
Number of subjects: 44
Study: 24240611

Group type: EXPERIMENTAL
Intervention: Mechanical CPR (LUCAS Chest Compression System)
Number of subjects: 2589

Group type: COMPARATOR
Intervention: Manual CPR (according to guidelines)
Number of subjects: 2589

Group type: EXPERIMENTAL
Intervention: Mechanical CPR
Number of subjects: 2589

Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 2589
Study: 22440214

Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe combination
Number of subjects: 1542

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1542
Study: 20578224

Group type: EXPERIMENTAL
Intervention: PEVI plus anticoagulation
Number of subjects: 169

Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 169
Study: 18050627

Group type: EXPERIMENTAL
Intervention: Acupuncture group (n=30) with manual acupuncture stimulation of Ganshu (BL18), Pishu (BL20), Zusanli (ST 36), once daily for 30 days, in addition to diet-control and medication (Gliguidone 30-60 mg, t.i.d. or insulin).
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (n=24) with diet-control and medication (Gliguidone 30-60 mg, t.i.d. or insulin).
Number of subjects: 54
Study: 16045376

Group type: EXPERIMENTAL
Intervention: Weight maintenance diet
Number of subjects: 188

Group type: COMPARATOR
Intervention: Assessment‐only controls
Number of subjects: 188
Study: 12394555

Group type: EXPERIMENTAL
Intervention: Nursing-based case management
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 66
Study: 10615719

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (2‐mg or 8‐mg tablets; maximum daily dose 8 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral methadone (racemic D ‐/+ L‐methadone; maximum daily dose 80 mg)
Number of subjects: 60
Study: 8960988

Group type: EXPERIMENTAL
Intervention: Intravaginal and oral misoprostol (100 micrograms intravaginally followed by 100 micrograms p.o. every 2 h)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Oxytocin/PGE2 gel (PGE2 cervical instillation 6 h before continuous oxytocin infusion)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (100 micrograms)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Oxytocin/PGE2 gel
Number of subjects: 224
Study: 1760601

Group type: EXPERIMENTAL
Intervention: Endometrial resection
Number of subjects: 51

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 51
Study: 6177963

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 11
Study: 31438789

Group type: EXPERIMENTAL
Intervention: Percutaneous trigger finger release combined with finger splint (group II)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Percutaneous release therapy regimen alone (group I)
Number of subjects: 65
Study: 29437032

Group type: EXPERIMENTAL
Intervention: Decision support group
Number of subjects: 46042

Group type: COMPARATOR
Intervention: No decision support group
Number of subjects: 46042
Study: 28779742

Group type: EXPERIMENTAL
Intervention: Garlic cloves at 20g.kg‐1 (T3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (T1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Garlic peels and cloves at 0, 10, 20, and 30g.kg‐1
Number of subjects: 0
Study: 24464736

Group type: COMPARATOR
Intervention: PIDS 0 ms mode
Number of subjects: 24

Group type: COMPARATOR
Intervention: PIDS optimized mode
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (PIDS off)
Number of subjects: 24
Study: 22913036

Group type: EXPERIMENTAL
Intervention: Immediate feedback during testing
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Repeated feedback
Number of subjects: 72
Study: 20935338

Group type: EXPERIMENTAL
Intervention: Center-based weight loss program
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Telephone-based weight loss program
Number of subjects: 442

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 442
Study: 17631069

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 0
Study: 15687128

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 30
Study: 11831544

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg for 7 days, followed by 400 mg for 21 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 10086200

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire
Number of subjects: 474

Group type: COMPARATOR
Intervention: Physician evaluation
Number of subjects: 474
Study: 7734740

Group type: EXPERIMENTAL
Intervention: Intensified treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 102
Study: 2073711

Group type: EXPERIMENTAL
Intervention: Metrifonate 2.5 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metrifonate 5 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metrifonate 7.5 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metrifonate 15 mg/kg
Number of subjects: 16
Study: 6760657

Group type: EXPERIMENTAL
Intervention: Acyclovir treatment
Number of subjects: 43
Study: 31598495

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 1 mic/kg at induction followed by 0.4 to 0.8 mic/kg/hour during maintenance
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group received normal saline instead of DEX
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 72
Study: 28240760

Group type: EXPERIMENTAL
Intervention: Focal muscle vibration therapy combined with progressive modular rebalancing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Focal muscle vibration therapy alone
Number of subjects: 0
Study: 25567476

Group type: EXPERIMENTAL
Intervention: Subcutaneous methylnaltrexone bromide 12 mg (MNTX group)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Saline (placebo group)
Number of subjects: 137
Study: 24216285

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 800
Study: 23135087

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray
Number of subjects: 2236

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray (monotherapy or add-on therapy)
Number of subjects: 2236
Study: 18564044

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Methylphenidate 40 mg
Number of subjects: 18
Study: 17513621

Group type: EXPERIMENTAL
Intervention: Morphine (40 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl (1000 microg)
Number of subjects: 30
Study: 17061994

Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal (1 mg/month)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (continued corticosteroids)
Number of subjects: 92
Study: 15261314

Group type: EXPERIMENTAL
Intervention: Dual-injection technique (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-injection technique (Group 1)
Number of subjects: 60
Study: 11192132

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg + metformin
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo + metformin
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Open-label pioglitazone + metformin
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 328
Study: 9359980

Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 1489024

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Balanced volatile technique with thiopentone/enflurane
Number of subjects: 50
Study: 3937407

Group type: EXPERIMENTAL
Intervention: Misoprostol (Mi) 100 mcg, 4 doses/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 29
Study: 31980954

Group type: EXPERIMENTAL
Intervention: PAV
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 18

Group type: COMPARATOR
Intervention: Baseline ventilation
Number of subjects: 18
Study: 31714945

Group type: EXPERIMENTAL
Intervention: Route choice model estimated with representative OD pairs
Number of subjects: 9

Group type: COMPARATOR
Intervention: Route choice model estimated over randomly selected OD pair configurations
Number of subjects: 9
Study: 28774880

Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m2 intravenously daily for 3 consecutive days on a 28-day cycle
Number of subjects: 113

Group type: COMPARATOR
Intervention: Azacitidine 75 mg/m2 intravenously/subcutaneously daily for 3 consecutive days on a 28-day cycle
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 113

Group type: COMPARATOR
Intervention: Azacitidine
Number of subjects: 113
Study: 25440646

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no RIPC)
Number of subjects: 30
Study: 23072448

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC) initiated with father
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC) initiated with mother
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC)
Number of subjects: 104
Study: 21444799

Group type: EXPERIMENTAL
Intervention: Cortisol (20 mg) administered orally 1 h before each treatment session
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo administered orally 1 h before each treatment session
Number of subjects: 40
Study: 19103797

Group type: EXPERIMENTAL
Intervention: 6-step essay strategy (analyzing the essay prompt, outlining, writing a response, and reviewing the answer)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what the control intervention was)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Students without learning disabilities (nominated by teachers as average writers)
Number of subjects: 0
Study: 16472043

Group type: EXPERIMENTAL
Intervention: Modeling intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15479319

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 43

Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 43
Study: 11138827

Group type: EXPERIMENTAL
Intervention: Age > 65 years
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Smoking years > 40 years
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure > 160 mmHg
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure > 100 mmHg
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Serum total cholesterol > 6.5 mmol/liter
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol > 1.5 mmol/liter
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: High energy intake (highest quartile)
Number of subjects: 29133
Study: 9576141

Group type: EXPERIMENTAL
Intervention: FP 50 microg, twice daily for 8 weeks
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: FP 100 microg, twice daily for 8 weeks
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: FP 200 microg/day (averaged over all visits)
Number of subjects: 138
Study: 7831448

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 89
Study: 3376919

Group type: EXPERIMENTAL
Intervention: Chewing gum (7 sticks for 15 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cheeseburger (chewed for 15 min)
Number of subjects: 12
Study: 30414275

Group type: EXPERIMENTAL
Intervention: Test cream (biomimetic, niacinamide-containing moisturizing cream) applied twice daily for 4 weeks
Number of subjects: 138

Group type: COMPARATOR
Intervention: No treatment (standard cleanser only)
Number of subjects: 138
Study: 29116597

Group type: EXPERIMENTAL
Intervention: Ixekizumab (160 mg subcutaneously 2 weeks prior and 80 mg on the day of vaccination)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (vaccinations alone)
Number of subjects: 83
Study: 25724983

Group type: EXPERIMENTAL
Intervention: Increasing walking activity
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Social approach for potential interventions
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Spoken content and delivery of interventions
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Local informal settings for interventions
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pedometers for self-monitoring
Number of subjects: 45
Study: 23369505

Group type: EXPERIMENTAL
Intervention: High-frequency random noise stimulation (tRNS) applied during task execution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) applied before task execution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study: 21683332

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted Descemet stripping endothelial keratoplasty (FS DSEK)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 80
Study: 18301939

Group type: EXPERIMENTAL
Intervention: General health surveillance in infancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concern about mother-child relationship
Number of subjects: 0
Study: 17062806

Group type: EXPERIMENTAL
Intervention: Combined people and pets (PP) exercising together (PPET) weight loss program
Number of subjects: 92

Group type: COMPARATOR
Intervention: Overweight or obese people only (PO)
Number of subjects: 92
Study: 15615667

Group type: EXPERIMENTAL
Intervention: Measures of impulsivity
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Measures of impulsive-aggression
Number of subjects: 92
Study: 10769438

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (0.5‐1 microgram/day) for 2 years
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 112
Study: 9126179

Group type: EXPERIMENTAL
Intervention: Jaw movement and surface EMG of the masseter and temporal muscles recorded during cycles with an impulse (5 N, 10 ms) applied at 8 different phases of the open-close cycle.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Jaw movement and surface EMG of the masseter and temporal muscles recorded during cycles without an impulse.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional external force of 20 N applied to the mandible during cycles.
Number of subjects: 0
Study: 1440175

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 3103169

Group type: EXPERIMENTAL
Intervention: 1 g intravenous aspirin
Number of subjects: 6

Group type: COMPARATOR
Intervention: 1 g oral aspirin
Number of subjects: 6
Study: 28873036

Group type: EXPERIMENTAL
Intervention: Action Observation Physical Training (AOPT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Landscape Imagery Observation Physical Training (LIOPT)
Number of subjects: 24
Study: 27193270

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 2917
Study: 24804842

Group type: EXPERIMENTAL
Intervention: Combination therapy (dutasteride + tamsulosin)
Number of subjects: 4722

Group type: COMPARATOR
Intervention: Dutasteride monotherapy
Number of subjects: 4722

Group type: COMPARATOR
Intervention: Tamsulosin monotherapy
Number of subjects: 4722
Study: 23680817

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day) plus modular CBT for 16 weeks, followed by maintenance escitalopram for 28 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Escitalopram alone followed by maintenance escitalopram
Number of subjects: 73

Group type: COMPARATOR
Intervention: Escitalopram plus CBT followed by pill placebo
Number of subjects: 73

Group type: COMPARATOR
Intervention: Escitalopram alone followed by placebo
Number of subjects: 73
Study: 20614521

Group type: EXPERIMENTAL
Intervention: Ecdisten (20 mg daily for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 0
Study: 18379166

Group type: EXPERIMENTAL
Intervention: Mask A (with exhaust valves)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mask B (with exhaust holes)
Number of subjects: 10
Study: 16981109

Group type: EXPERIMENTAL
Intervention: Simplified ingestion procedure (SIP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Original ingestion procedure
Number of subjects: 24
Study: 14552094

Group type: EXPERIMENTAL
Intervention: Management of vascular accesses (VA) in European dialysis centres
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous vascular accesses and interventions before first use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurses' role in prevention and management of VA complications
Number of subjects: 0
Study: 11216327

Group type: EXPERIMENTAL
Intervention: Traumatic group (TG) with intraoral traumatic factors
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-traumatic group (NTG) without intraoral traumatic factors
Number of subjects: 110
Study: 9172847

Group type: EXPERIMENTAL
Intervention: Preoperative teaching with an ICU tour (patients, n = 44; family members, n = 43)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Preoperative teaching only (control group, patients, n = 48; family members, n = 48)
Number of subjects: 183
Study: 8380567

Group type: EXPERIMENTAL
Intervention: 72 Gy hyperfractionated radiation therapy + BCNU (80 mg/m2 on days 3, 4, 5 of radiation therapy and then every 8 weeks for 1 year)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: 81.6 Gy hyperfractionated radiation therapy + BCNU
Number of subjects: 435

Group type: COMPARATOR
Intervention: Lower radiation dose range (60-74.4 Gy)
Number of subjects: 435

Group type: COMPARATOR
Intervention: 60 Gy conventional fractionation + BCNU
Number of subjects: 435
Study: 3717993

Group type: EXPERIMENTAL
Intervention: Simple, incentive based behaviour modification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modest programme of psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social disadvantage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Failure to respond to treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fairly simple programmes
Number of subjects: 0

Group type: COMPARATOR
Intervention: More elaborate and expensive strategies
Number of subjects: 0
Study: 29526378

Group type: EXPERIMENTAL
Intervention: pEVAR
Number of subjects: 50

Group type: COMPARATOR
Intervention: cEVAR
Number of subjects: 50
Study: 26350485

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline solution injections (control)
Number of subjects: 50
Study: 24938176

Group type: EXPERIMENTAL
Intervention: PRO 160/120 (sabal and urtica extracts)
Number of subjects: 922

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 922
Study: 23252453

Group type: EXPERIMENTAL
Intervention: Silodosin (4 mg twice daily)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Naftopidil (50 mg once daily)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Silodosin
Number of subjects: 121

Group type: COMPARATOR
Intervention: Naftopidil
Number of subjects: 121
Study: 20575258

Group type: EXPERIMENTAL
Intervention: DTaP-Hib vaccine
Number of subjects: 690

Group type: COMPARATOR
Intervention: DTaP+Hib separately
Number of subjects: 690
Study: 17568589

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 microg/kg/min for 24 hours)
Number of subjects: 26
Study: 17083354

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 14705689

Group type: EXPERIMENTAL
Intervention: Full-body forced-air cover
Number of subjects: 18

Group type: COMPARATOR
Intervention: Blanket (control)
Number of subjects: 18
Study: 12093769

Group type: EXPERIMENTAL
Intervention: Doppler strain rate echocardiography
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Doppler strain rate echocardiography during dobutamine infusion
Number of subjects: 58

Group type: COMPARATOR
Intervention: Doppler strain rate echocardiography vs tagged MRI
Number of subjects: 58
Study: 12038477

Group type: EXPERIMENTAL
Intervention: Wheat bran with mean particle size (MPS) 50 microm
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Wheat bran with mean particle size (MPS) 758 microm
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Wheat bran with mean particle size (MPS) 692 microm
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Wheat bran with mean particle size (MPS) 1158 microm
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control low fiber bread
Number of subjects: 47
Study: 8747670

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Meridol (amine fluoride/stannous fluoride solution)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Listerine (phenolic compound)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control solution (0.02% quinine-hydrochloride)
Number of subjects: 40
Study: 1776404

Group type: EXPERIMENTAL
Intervention: Vitamin replacement therapy (B1, B2, B6)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 16
Study: 6182343

Group type: EXPERIMENTAL
Intervention: Aggressive protocol using adriamycin, cyclophosphamide, vincristine, dacarbazine for remission induction; additional randomized group received high dose β‐interferon.
Number of subjects: 140